Canary Bio Accelerates Commercialization Preparations... Operates Exhibition Booth at ASCO

Canaria Bio announced on the 4th that it will present a poster on the ovarian cancer immuno-oncology drug Oregobomab at the American Society of Clinical Oncology Annual Meeting (ASCO 2023) held from June 2 to 6. The company will also set up an exhibition booth where CEO Han-Ik Na and Head of Medical and Pharmaceutical Development Dr. Jada will directly engage with participants.

CEO Han-Ik Na stated, “As part of our commercialization strategy, we will actively market Oregobomab starting this year. We plan to operate exhibition booths at major conferences whenever possible. Before the launch, we aim to establish strong recognition of Oregobomab among patients and physicians to achieve peak sales as quickly as possible after the product release.”

At the end of last year, Canaria Bio recruited Dr. Jada, formerly of BMS, and established a dedicated Medical Affairs team. Dr. Jada is a commercialization strategy expert who has led Medical Affairs teams not only at BMS but also at Merck and AstraZeneca.

Dr. Jada said, “Since chemotherapy remains the predominant treatment for ovarian cancer, I sensed the commercial potential of Oregobomab after seeing the remarkable results from its Phase 2 clinical trial. If the Phase 3 trial succeeds, it could become a must-use drug for new ovarian cancer patients.”

Meanwhile, Oregobomab, the ovarian cancer immuno-oncology drug, is known as a new drug that showed encouraging results in the Phase 2 clinical trial, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months.

This content was produced with the assistance of AI translation services.